Lallemand Health Ingredients (LHI) and Decas Botanical Synergies (DBS), a subsidiary of Decas Cranberry Products, Inc., has announced the overall results of a second randomized clinical trial substantiating the efficacy of a premium PAC-standardized whole cranberry powder PACran in the prevention of recurrent urinary tract infections (UTI) in women. The new study followed Good Clinical Practice (GCP) and was conducted by the team of Dr Vidlar from the Department of Urology, University Hospital in Olomouc, Czech Republic. The first data was presented last week at the 15th annual PhytoPharm congress in Nuremberg and makes PACran the first and only PAC-standardized whole cranberry powder backed by two controlled clinical studies. PACran is distributed in Europe by Lallemand Health Ingredients, and suitable for the formulation of clinically supported food supplements of all galenic forms.
Julie Rosenborg, Product manager for Cranberry Ingredients for Lallemand Health Ingredients commented: “A recent market study (source: Innova Market Insights, 2011) has ranked ‘proven‘ as number one health trend. We are pleased to offer our customer the Whole Cranberry Powder with the strongest pool of clinical evidence on the market and are ready to support them in the development and marketing of innovative products addressing the urinary health segment.”
The aim of the 6 month intervention trial was to assess the efficacy of a daily dose of 500 mg of PACran in women with a history of recurrent UTIs. 165 women in total participated in the randomized study (79 in the PACran group, 86 in the placebo group). During the six months of the trial, there were 22 UTI events in the placebo group vs. 11 in the PAcran group.
The recurrence rate for the cranberry group was 14.2%, vs. 25.7% in the placebo group. This corresponds to an absolute reduction in UTI recurrence of 15%. These data further validate that a 500 mg daily dose of PACran is effective in reducing the recurrence of urinary tract infections in women.
The previous clinical trial with PACran in UTI prevention was published in April 2011 (1) and showed that the daily consumption of 500 mg of PACran by women suffering from recurrent UTIs was effective in both reducing the number of E. coli positive subjects and ameliorating the symptoms of UTI in these subjects. This is further supported by ex vivo data from Rutgers University (New Jersey) showing that the consumption of 500 mg PACran conferred the same level of ex vivo urinary anti-adhesion activity against uropathogenic E. coli over a 24-hour period as 300 ml of Cranberry Juice Cocktail containing 36 mg Proanthocyandines.
“PACran has been built from the ground up to deliver cranberry in support of urinary tract health,” said Rahul Shinde, Research Scientist for Decas Botanical Synergies. “This is the second clinical trial to show positive results for PACran’s support for women with urinary health issues. These results build on the extensive library of science we have developed in support of PACran.”
PACran is the cranberry constituent in Lallemand’s innovative probiotic & cranberry combination product - Cysbiotic, – targeting womens’ health. Associating the documented probiotic strain Lactobacillus Rhamnosus R-11 and PACran in a capsule stable at room temperature, Cysbiotic is recommended to support urinary tract health and improve gastrointestinal health.
Urinary Tract Infection (UTI) is the most common infection among women and has a high reoccurrence rate. Its main causative agent is E. Coli bacteria. Foxman et al. have shown that nearly 1 in 3 women will have had at least one episode of UTI requiring antimicrobial therapy before they reach 24 years of age. Another study estimates that nearly half of the women who have had a UTI will experience another one within 12 months (Ikäheimo et al. 1996).Cranberries are widely documented for their preventive effect against urinary tract infection, thanks to their unique anti-adhesion activity. This activity is primarily due to the presence of key phytochemicals: proanthocyanidines (PACs). PACs are present in other plants, but cranberry have been shown to contain a unique A-type PAC, while most other fruits contain only the more common B-type PACs. Researchers have linked the presence of A-type PAC in cranberry to its unique anti-adherence effect against pathogenic bacteria.PACran is the world’s first proanthocyanidin (PAC) standardized cranberry powder substantiated by two randomized clinical trials. PACran is produced in US using PAC-rich Early Black cranberries of the North American species (Vaccinium Macrocarpon) and has been clinically shown to support urinary tract health at a 500 mg daily dose. The unique patented formula of PACran provides superior potency at a substantially lower cost per dose. PACran is the first cranberry product in the world with a government sanctioned health claim. The Korean Food and Drug Administration (KFDA) in 2009 reviewed the complete clinical dossier and awarded PACran with a permissible urinary health claim. PACran is also the only cranberry product clinically shown to support prostate health (Vidlar, et. al. – British Journal of Nutrition, 2010).
Lallemand Health Ingredients manages the sales and service of strategic health ingredients to the dietary food supplements and functional food markets worldwide.
Julie Rosenborg, Product manager for Cranberry Ingredients for Lallemand Health Ingredients commented: “A recent market study (source: Innova Market Insights, 2011) has ranked ‘proven‘ as number one health trend. We are pleased to offer our customer the Whole Cranberry Powder with the strongest pool of clinical evidence on the market and are ready to support them in the development and marketing of innovative products addressing the urinary health segment.”
The aim of the 6 month intervention trial was to assess the efficacy of a daily dose of 500 mg of PACran in women with a history of recurrent UTIs. 165 women in total participated in the randomized study (79 in the PACran group, 86 in the placebo group). During the six months of the trial, there were 22 UTI events in the placebo group vs. 11 in the PAcran group.
The recurrence rate for the cranberry group was 14.2%, vs. 25.7% in the placebo group. This corresponds to an absolute reduction in UTI recurrence of 15%. These data further validate that a 500 mg daily dose of PACran is effective in reducing the recurrence of urinary tract infections in women.
The previous clinical trial with PACran in UTI prevention was published in April 2011 (1) and showed that the daily consumption of 500 mg of PACran by women suffering from recurrent UTIs was effective in both reducing the number of E. coli positive subjects and ameliorating the symptoms of UTI in these subjects. This is further supported by ex vivo data from Rutgers University (New Jersey) showing that the consumption of 500 mg PACran conferred the same level of ex vivo urinary anti-adhesion activity against uropathogenic E. coli over a 24-hour period as 300 ml of Cranberry Juice Cocktail containing 36 mg Proanthocyandines.
“PACran has been built from the ground up to deliver cranberry in support of urinary tract health,” said Rahul Shinde, Research Scientist for Decas Botanical Synergies. “This is the second clinical trial to show positive results for PACran’s support for women with urinary health issues. These results build on the extensive library of science we have developed in support of PACran.”
PACran is the cranberry constituent in Lallemand’s innovative probiotic & cranberry combination product - Cysbiotic, – targeting womens’ health. Associating the documented probiotic strain Lactobacillus Rhamnosus R-11 and PACran in a capsule stable at room temperature, Cysbiotic is recommended to support urinary tract health and improve gastrointestinal health.
Urinary Tract Infection (UTI) is the most common infection among women and has a high reoccurrence rate. Its main causative agent is E. Coli bacteria. Foxman et al. have shown that nearly 1 in 3 women will have had at least one episode of UTI requiring antimicrobial therapy before they reach 24 years of age. Another study estimates that nearly half of the women who have had a UTI will experience another one within 12 months (Ikäheimo et al. 1996).Cranberries are widely documented for their preventive effect against urinary tract infection, thanks to their unique anti-adhesion activity. This activity is primarily due to the presence of key phytochemicals: proanthocyanidines (PACs). PACs are present in other plants, but cranberry have been shown to contain a unique A-type PAC, while most other fruits contain only the more common B-type PACs. Researchers have linked the presence of A-type PAC in cranberry to its unique anti-adherence effect against pathogenic bacteria.PACran is the world’s first proanthocyanidin (PAC) standardized cranberry powder substantiated by two randomized clinical trials. PACran is produced in US using PAC-rich Early Black cranberries of the North American species (Vaccinium Macrocarpon) and has been clinically shown to support urinary tract health at a 500 mg daily dose. The unique patented formula of PACran provides superior potency at a substantially lower cost per dose. PACran is the first cranberry product in the world with a government sanctioned health claim. The Korean Food and Drug Administration (KFDA) in 2009 reviewed the complete clinical dossier and awarded PACran with a permissible urinary health claim. PACran is also the only cranberry product clinically shown to support prostate health (Vidlar, et. al. – British Journal of Nutrition, 2010).
Lallemand Health Ingredients manages the sales and service of strategic health ingredients to the dietary food supplements and functional food markets worldwide.
Headquartered in Carver, Massachusetts, Decas Botanical Synergies, a subsidiary of Decas Cranberry Products, Inc., is a developer, manufacturer and marketer of patented, value-added fruit-derived ingredients for the dietary supplement, functional foods, animal feed and nutrition, personal care and cosmetics, and oral health industries.
Source:Pharmabiz
No comments:
Post a Comment